RBC Capital analyst Luca Issi maintained a Hold rating on Editas Medicine (EDIT – Research Report) on February 24 and set a price target of $40.00. The company’s shares closed last Friday at $16.90, close to its 52-week low of $13.25.
According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of -27.4% and a 21.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $26.75 average price target, implying a 67.8% upside from current levels. In a report issued on February 11, Evercore ISI also downgraded the stock to Hold with a $15.00 price target.
Editas Medicine’s market cap is currently $1.16B and has a P/E ratio of -5.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More on EDIT:
- Flowserve (FLS) Receives a Hold from RBC Capital
- RBC Capital Maintains a Hold Rating on BioCryst (BCRX)
- Dream Office Real Estate Investment (DRETF) Receives a Hold from RBC Capital
- Kepler Capital Thinks Tecan Group AG’s Stock is Going to Recover
- Equitrans Midstream (ETRN) Gets a Hold Rating from RBC Capital